$BMY News Market rookie Five Prime's shares surg
Post# of 44884

Market rookie Five Prime's shares surge on deal with Bristol-Myers 12:01 p.m. March 17, 2014 - Russ Britt
RadioShack sinks; J.C. Penney gains on S&P outlook hike 5:19 p.m. March 4, 2014 - Sue Chang
Bristol-Myers plans late-stage tests on Yervoy as lung-cancer treatment 5:01 p.m. March 4, 2014 - Russ Britt
Billionaire Stan Druckenmiller's recent moves 12:50 p.m. Feb. 24, 2014 - Insider Monkey
Feds, pharma rivals team up on Alzheimer's 3:32 p.m. Feb. 6, 2014 - Elizabeth O'Brien
Merck hits a new high as analyst sees opening for new cancer drug 12:16 p.m. Jan. 27, 2014 - Russ Britt
U.S. stocks tumble; Dow drops 318 points 6:29 p.m. Jan. 24, 2014 - Anora Mahmudova
Juniper buoyed by Jana stake; Herbalife loss grows 4:50 p.m. Jan. 24, 2014 - Sue Chang
U.S. stock futures trim losses ahead of market open 9:57 a.m. Jan. 24, 2014 - Barbara Kollmeyer
Beam, Honeywell, Procter & Gamble are stocks to watch 6:38 a.m. Jan. 24, 2014 - Sue Chang
AstraZeneca, Bristol-Myers Secure EU OK for Xigduo 3:44 a.m. Jan. 22, 2014 - MarketWatch.com
‘Sloppy’ market turns to consumer, tech earnings 9:01 a.m. Jan. 19, 2014 - Wallace Witkowski
America's best and most generous 401(k)s 3:30 p.m. Jan. 15, 2014 - Anne Tergesen
Merck initiates melanoma filing with FDA 12:45 p.m. Jan. 13, 2014 - Tess Stynes
Statin usefulness questioned, but patent expirations may ease pain 2:02 p.m. Jan. 8, 2014 - Russ Britt
Not all pharmaceuticals are created equal 1:40 p.m. Dec. 26, 2013 - The Trading Deck
FTSE 100 rises, shaking off retail data after Fed taper 1:06 p.m. Dec. 19, 2013 - Sara Sjolin
European stocks rally on Fed taper, rate views 1:00 p.m. Dec. 19, 2013 - Sara Sjolin
AstraZeneca to buy Bristol-Myers diabetes-JV stake 4:25 a.m. Dec. 19, 2013 - MarketWatch.com
Pfizer and Kaiser: They not only rhyme, they're in sync with workers 12:12 p.m. Dec. 10, 2013 - Russ Britt
Tradable Biotech Stocks Events For the Second Quarter 9:00 a.m. Today - TheStreet.com
Why Bristol-Myers Squibb is a Top 25 Dividend Giant (BMY) 5:35 a.m. Today - InvestorPlace.com
China still bright for Big Pharma 11:30 a.m. April 2, 2014 - Seeking Alpha
Glaxo Suffers Another Setback 5:26 a.m. April 2, 2014 - The Wall Street Journal Interactive Edition
3 Stocks Pushing The Drugs Industry Lower 1:03 p.m. April 1, 2014 - TheStreet.com
Sales Soar for Pricey Hepatitis Drug Sovaldi 8:16 p.m. March 31, 2014 - The Wall Street Journal Interactive Edition
Which Pharmas Can Keep Up Dividend-Buybacks? 3:02 p.m. March 31, 2014 - Seeking Alpha
Amgen Stock Gets Bump Up On Cholesterol Drug Data 12:59 p.m. March 31, 2014 - Investors Business Daily
3 Stocks Reiterated As A Buy: MA, SLB, BMY 12:18 p.m. March 31, 2014 - TheStreet.com
Cramer: Keep an Eye on Celgene (CELG), Gilead (GILD), Isis Pharmaceuticals (ISIS) and Seattle Genetics (SGEN) 12:03 p.m. March 31, 2014 - TheStreet.com
Don't Give Up On Momentum 8:36 p.m. March 28, 2014 - Seeking Alpha
Gilead Sovaldi Scrips Falter As Biotechs Keep Falling 3:42 p.m. March 28, 2014 - Investors Business Daily
Government agency plans to shake down Big Pharma 1:54 p.m. March 28, 2014 - Seeking Alpha
A Look Back At Big Pharma Stocks 4:58 p.m. March 27, 2014 - Seeking Alpha
Bristol-Myers Still Lags in Hepatitis C 8:19 a.m. March 27, 2014 - Barrons.com
Jim Cramer's 'Mad Money' Recap: Beware the Vacuum 8:03 p.m. March 26, 2014 - TheStreet.com
3 Stocks Reiterated As A Buy: MSFT, BMY, CAT 12:14 p.m. March 26, 2014 - TheStreet.com
J.P. Morgan Says Buy Specialty and Big Pharmaceuticals Now 8:15 a.m. March 26, 2014 - 247WallSt.com
Novo Nordisk Upgraded to 'Buy' 11:43 a.m. March 24, 2014 - FOXBusiness
Drug Firms Focus on Advanced Melanoma 8:11 p.m. March 23, 2014 - The Wall Street Journal Interactive Edition
Theravance Appoints Kevin Kwok, Head of Talent Acquisition and Strategy 4:05 p.m. April 1, 2014 - Marketwire
Bristol-Myers Squibb to Announce Results for First Quarter 2014 on April 29 9:00 a.m. April 1, 2014 - BusinessWire - BZX
Bristol-Myers Squibb Executive Maclean Becomes Precision Health Economics' Chief Operating Officer 10:22 a.m. March 31, 2014 - PR Newswire - PRF
INNATE PHARMA : Start of cohort expansion of Phase I trial with lirilumab and nivolumab in selected solid tumors 1:50 a.m. March 31, 2014 - GlobeNewswire
In A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure Control 1 8:16 a.m. March 27, 2014 - BusinessWire - BZX
NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool 4:51 p.m. March 26, 2014 - PR Newswire - PRF
Pharmaceutical Executive to Unveil Brand of the Year Award Recipients at iPharma 2014: CBI's Marketing Innovation Summit 12:11 p.m. March 26, 2014 - PR Newswire - PRF
Five Prime Therapeutics Announces Fourth Quarter and Fiscal 2013 Financial Results 4:30 p.m. March 25, 2014 - GlobeNewswire
Tocagen Names Jamey Skillings, M.D., Chief Medical Officer 8:00 a.m. March 25, 2014 - PR Newswire - PRF
Bristol-Myers Squibb to Present Data for Daclatasvir in Multiple Investigational All-oral Combinations across Hepatitis C Genotypes at The International Liver CongressTM 5:39 a.m. March 24, 2014 - BusinessWire - BZX
FDA Approvals, Financial Highlights, Restated Treatment Indications, and Updates on Product Pipelines - Analyst Notes on Bristol-Myers Squibb, Galena, Teleflex, GW Pharmaceuticals, and CytRx 8:00 a.m. March 21, 2014 - PR Newswire - PRF
Trace One Names Mark Martini as Vice President of North America to Lead Sales and Customer Development 9:01 a.m. March 20, 2014 - BusinessWire - BZX
Portola Pharmaceuticals Initiates Phase 3 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, Under Accelerated Approval Pathway 8:15 a.m. March 19, 2014 - GlobeNewswire
Health Care Stocks Review -- Research on Bristol-Myers Squibb, Johnson & Johnson, Merck & Co. and Eli Lilly 8:00 a.m. March 19, 2014 - PR Newswire - PRF
Five Prime Therapeutics and Bristol-Myers Squibb Sign Collaboration Agreement to Discover Novel Immuno-Oncology Therapies for Two Immune Checkpoint Pathways 6:59 a.m. March 17, 2014 - BusinessWire - BZX
Five Prime Therapeutics and Bristol-Myers Squibb Sign Collaboration Agreement to Discover Novel Immuno-Oncology Therapies for Two Immune Checkpoint Pathways 6:59 a.m. March 17, 2014 - GlobeNewswire
U.S. FDA Approves Eliquis® (apixaban) To Reduce The Risk Of Blood Clots Following Hip Or Knee Replacement Surgery 1:00 p.m. March 14, 2014 - BusinessWire - BZX
Investment Grants, Data Presentations, Clinical Study Results, and Collaborative Programs - Analyst Notes on UnitedHealth Group, Bristol-Myers Squibb, AbbVie, Cigna, and OXiGENE 8:00 a.m. March 14, 2014 - PR Newswire - PRF
Pharma-Biotech Industry Helps Drive $14.4 Billion Industrial Project Activity in Massachusetts, an Industrial Info News Alert 6:30 a.m. March 10, 2014 - Marketwire
Medivir: SVR12 Results from a Phase IIa Study Evaluating Simeprevir and Daclatasvir in Hepatitis C Patients of Genotype 1 Have Been Presented 12:30 p.m. March 4, 2014 - BusinessWire - BZX

